Kaspofungin Pliva

Caspofungin, the active ingredient in Kaspofungin Pliva, is an echinocandin presented as an intravenous formulation for hospital use. It is employed to treat serious fungal infections such as invasive candidiasis, esophageal candidiasis, and invasive aspergillosis in immunocompromised patients.

GNH USA supplies Kaspofungin Pliva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides reliable logistics for clinical settings.

Caspofungin is an echinocandin antifungal used for systemic fungal infections.

- Invasive candidiasis: effective in clearing bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection and associated symptoms. - Invasive aspergillosis: provides a therapeutic option for patients with proven or probable disease.

Caspofungin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fever - Chills - Nausea - Headache - Elevated liver enzymes (ALT/AST)

Serious or Rare Side Effects: - Severe hepatic dysfunction - Anaphylactic reaction - Acute renal failure - Severe hypotension or cardiovascular collapse

When using caspofungin, clinicians should observe several precautionary measures to minimize risk.

- Liver function monitoring: assess transaminases before and during therapy. - Renal function monitoring: evaluate serum creatinine and urine output. - Dose adjustment: consider reduced dosing in patients with moderate hepatic impairment. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Concomitant cardiotoxic drugs: use with caution in patients with heart failure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Caspofungin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Rifampin or other strong CYP3A4 inducers: markedly reduce caspofungin exposure. - Cyclosporine: co‑administration may increase cyclosporine concentrations, risking toxicity. - Strong azole inhibitors (e.g., ketoconazole): may increase caspofungin levels.

Moderate Interactions (Monitor Closely): - Fluconazole or voriconazole: may modestly raise caspofungin exposure. - Warfarin: monitor INR as caspofungin may affect anticoagulant effect. - Statins metabolized by CYP3A4: observe for possible increased statin levels.